Strengthening its clinical research service offerings in China and the US, contract research organization (CRO)
K&L Consulting Services
(K&L), Inc. has expanded its relationship with
(NASDAQ: MDSO) by achieving multiple accreditations in the
Medidata Clinical Cloud
. With this milestone, K&L is now accredited to provide services around the industry-leading
system for electronic data capture (EDC) and clinical data management (CDM) as well as randomization services utilizing
With a focus on biostatistical analysis, data standardization and a prominent presence in China, K&L joined the
Medidata Partner Program
in 2011 as a Medidata Services Partner to help serve sponsors within Asia and abroad. Impressed with Medidata’s standards-based approach to end-to-end clinical development, K&L saw value in extending the partnership to take greater advantage of Rave's easy-to-use platform and streamlined processes to help sponsors prepare regulatory submissions. K&L is currently utilizing Medidata Rave for several studies within Asia; and with its continued growth in the region, it expects the Medidata platform to play a vital role in helping sponsors streamline their clinical trials.
- “Partnering with Medidata enables us to offer sponsors state-of-the-art solutions for the critically important activities of randomization, electronic data capture and clinical data management,” said Xin Ke, PhD, president, K&L. “The Medidata Clinical Cloud, combined with our sophisticated services, provides sponsors with a highly-valued offering that ultimately reduces risk and leads to faster drug approvals.”
The Medidata accreditations position K&L to serve as a single source for Balance-related randomization design services and Rave-related services, including end user training, study build, reporting, outputs, integrations and migrations. Using Balance and Rave, sites can use just one browser interface—Medidata Rave—to randomize subjects and manage clinical data entry and reporting.
- “With these accreditations, K&L strengthens its commitment to providing sponsors with increasing efficiencies across their clinical trials,” said Steve Heath, vice president of channel sales at Medidata Solutions. “We’re excited to collaborate with K&L to help life science organizations both in the US and the growing market in China.”
Medidata first announced its channel partner program in April 2005 to enable select CROs and other service providers to offer implementation services for the Medidata Rave system for EDC and CDM. Since then, the Medidata Partner Program has grown to include more than 30 partners in the US, Europe and Asia, ranging from smaller clinical consultancies to large, global CROs. The program offers
across the Medidata platform and supports partners with a variety of on-demand resources to help them optimize sponsors’ clinical trials.
Connect with Medidata:
About K&L Consulting Services, Inc.
K&L Consulting Services, Inc.
is a contract research organization (CRO) offering data management, biostatistics, statistical programming, and medical writing as well as CDISC compliant eSubmission services to the pharmaceutical, biotechnology and medical device industries worldwide. Their services encompass end-to-end solutions utilizing industry data standards and rigorous operating procedures that enhance a sponsor's ability to get their products approved faster at minimum risk and lower cost in order to meet patients’ needs for advanced medicines.
About Medidata Solutions Worldwide
is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.